<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Hepatitis B Virus (HBV)</title>
	<atom:link href="http://www.xhbv.com/feed" rel="self" type="application/rss+xml" />
	<link>http://www.xhbv.com</link>
	<description>Hepatitis B is a disease caused by HBV hepatitis B virus which infects the liver of hominoidae, including humans, and causes an inflammation called hepatitis</description>
	<lastBuildDate>Fri, 16 Jul 2010 02:01:39 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Co-packaging Compliance Conundrum</title>
		<link>http://www.xhbv.com/co-packaging-compliance-conundrum.html</link>
		<comments>http://www.xhbv.com/co-packaging-compliance-conundrum.html#comments</comments>
		<pubDate>Fri, 16 Jul 2010 02:01:39 +0000</pubDate>
		<dc:creator>Daniel Amsel</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Compliance Conundrum]]></category>

		<guid isPermaLink="false">http://www.xhbv.com/?p=1354</guid>
		<description><![CDATA[Medication compliance is a hot topic these days, both in Washington and beyond the Beltway. For example, one of the concerns PBMs have had about a medical data privacy law is that they might not be able to get the kind of patient information they need—from pharmacies or physicians—to run the kind of compliance programs [...]]]></description>
		<wfw:commentRss>http://www.xhbv.com/co-packaging-compliance-conundrum.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond Bar Codes: FindtheDOT</title>
		<link>http://www.xhbv.com/beyond-bar-codes-findthedot.html</link>
		<comments>http://www.xhbv.com/beyond-bar-codes-findthedot.html#comments</comments>
		<pubDate>Thu, 15 Jul 2010 02:01:38 +0000</pubDate>
		<dc:creator>Daniel Amsel</dc:creator>
				<category><![CDATA[Main]]></category>
		<category><![CDATA[Bar Codes]]></category>

		<guid isPermaLink="false">http://www.xhbv.com/?p=1355</guid>
		<description><![CDATA[
Most of our readers are working hard in hospitals, managed care organizations, and other settings to reduce the epidemic of medical errors, especially those relating to the delivery of prescription medication. Indeed, volumes have now been written about medical error reduc-tion, and major national organizations are spreading the error-reduction gospel everyday. Progress appears to be [...]]]></description>
		<wfw:commentRss>http://www.xhbv.com/beyond-bar-codes-findthedot.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bar Coding Pharmaceuticals</title>
		<link>http://www.xhbv.com/bar-coding-pharmaceuticals.html</link>
		<comments>http://www.xhbv.com/bar-coding-pharmaceuticals.html#comments</comments>
		<pubDate>Wed, 14 Jul 2010 02:05:43 +0000</pubDate>
		<dc:creator>Daniel Amsel</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.xhbv.com/?p=1356</guid>
		<description><![CDATA[After a few years of revving up its regulatory engine, the Food and Drug Administra- tion (FDA) is ready to move forward with a proposal for bar coding pharmaceuticals. The idea is to use bar coding to cut down on the kinds of medication errors that were first highlighted in the National Academy of Science&#8217;s [...]]]></description>
		<wfw:commentRss>http://www.xhbv.com/bar-coding-pharmaceuticals.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Surviving Drug Shortages: Committee Approvals</title>
		<link>http://www.xhbv.com/surviving-drug-shortages-committee-approvals.html</link>
		<comments>http://www.xhbv.com/surviving-drug-shortages-committee-approvals.html#comments</comments>
		<pubDate>Mon, 12 Jul 2010 11:08:12 +0000</pubDate>
		<dc:creator>Daniel Amsel</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Shortages]]></category>
		<category><![CDATA[Surviving Drug]]></category>

		<guid isPermaLink="false">http://www.xhbv.com/?p=1346</guid>
		<description><![CDATA[Depending on the drug-shortage profile, task forces might be created to determine what, if any, restrictions or interchanges are appropriate. Subsequently, the information is presented at the drug use committee and drug use and formulary review subcommittee of the P&#38;T committee. Ultimately, the P&#38;T committee reviews and accepts formulary recommendations and distributes communications about the [...]]]></description>
		<wfw:commentRss>http://www.xhbv.com/surviving-drug-shortages-committee-approvals.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Surviving Drug Shortages: Assessment of Shortage</title>
		<link>http://www.xhbv.com/surviving-drug-shortages-assessment-of-shortage.html</link>
		<comments>http://www.xhbv.com/surviving-drug-shortages-assessment-of-shortage.html#comments</comments>
		<pubDate>Sun, 11 Jul 2010 11:08:11 +0000</pubDate>
		<dc:creator>Daniel Amsel</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Shortages]]></category>
		<category><![CDATA[Surviving Drug]]></category>

		<guid isPermaLink="false">http://www.xhbv.com/?p=1345</guid>
		<description><![CDATA[During the assessment phase, the coordinator of purchasing and inventory control determines the duration and reason for the shortage. If it is determined that a short-term shortage will occur, drug quantities are ordered based on allocation by the wholesaler. If long-term shortages or unexpected emergent shortages are confirmed, the director of pharmacy delegates clinical assessments [...]]]></description>
		<wfw:commentRss>http://www.xhbv.com/surviving-drug-shortages-assessment-of-shortage.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Surviving Drug Shortages</title>
		<link>http://www.xhbv.com/surviving-drug-shortages.html</link>
		<comments>http://www.xhbv.com/surviving-drug-shortages.html#comments</comments>
		<pubDate>Sat, 10 Jul 2010 11:08:10 +0000</pubDate>
		<dc:creator>Daniel Amsel</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Shortages]]></category>
		<category><![CDATA[Surviving Drug]]></category>

		<guid isPermaLink="false">http://www.xhbv.com/?p=1344</guid>
		<description><![CDATA[
The incidence of significant drug shortages has been gradually increasing since the early 1990s. Reasons for the drug shortages have included, but are not limited to, a lack of raw materials, manufacturing difficulties, voluntary recalls, and shutdowns of manufacturing plants by the Food and Drug Administration (FDA). Also, there have been more occurrences as pharmaceutical [...]]]></description>
		<wfw:commentRss>http://www.xhbv.com/surviving-drug-shortages.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Highlights of the Second Annual P&amp;T Society Meeting: Current Political and Prescription Benefits Environment</title>
		<link>http://www.xhbv.com/highlights-of-the-second-annual-pt-society-meeting-current-political-and-prescription-benefits-environment.html</link>
		<comments>http://www.xhbv.com/highlights-of-the-second-annual-pt-society-meeting-current-political-and-prescription-benefits-environment.html#comments</comments>
		<pubDate>Fri, 09 Jul 2010 09:34:54 +0000</pubDate>
		<dc:creator>Daniel Amsel</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Second Annual]]></category>
		<category><![CDATA[Society Meeting]]></category>

		<guid isPermaLink="false">http://www.xhbv.com/?p=1333</guid>
		<description><![CDATA[
Speaker: Terry S. Latanich, JD, Senior Vice President for Government Affairs, Merck-Medco, Franklin Lakes, New Jersey.
Mr. Latanich&#8217;s presentation covered the Medicare drug benefit, Medicare-endorsed prescription cards, re-importation of prescription drugs, the Patient&#8217;s Bill of Rights (PBOR), generics legislation, and issues affecting the composition of P&#38;T committees.
The Medicare drug benefit passed in the House of Representatives [...]]]></description>
		<wfw:commentRss>http://www.xhbv.com/highlights-of-the-second-annual-pt-society-meeting-current-political-and-prescription-benefits-environment.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
